Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

This article is part of the Research TopicThe Role of Immunotherapy in Cancer Therapy and Its ChallengesView all 27 articles

Analyses on patterns of lymph node metastasis and its impact on prognosis in thoracic esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy versus chemotherapy alone: A single-center, retrospective cohort study

Provisionally accepted
Weibin  LiuWeibin Liu1Yujie  DengYujie Deng2Xuejin  ZhengXuejin Zheng3Weikun  SuWeikun Su1Jianqing  ZhengJianqing Zheng4Yijin  LinYijin Lin1Weijin  XiaoWeijin Xiao1Yi  ShiYi Shi1Jiarong  ZhangJiarong Zhang1Weimin  FangWeimin Fang1Xiaohui  ChenXiaohui Chen1,3*
  • 1Fujian Provincial Cancer Hospital Clinical Oncology School, Fuzhou, China
  • 2The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
  • 3Fuzhou University School of Chemical Engineering, Fuzhou, China
  • 4Second Affiliated Hospital of Fujian Medical University, Quanzhou, China

The final, formatted version of the article will be published soon.

Objective: To compare the patterns of lymph node metastasis (LNM) in patients with thoracic esophageal squamous cell carcinoma (TESCC) treated with neoadjuvant immunochemotherapy (nICT) versus neoadjuvant chemotherapy (nCT) alone and its impact on prognosis and potential clinical implications. Methods: A single-center retrospective cohort study was conducted on 441 patients with locally advanced TESCC who underwent nCT (n=179) or nICT (n=262) followed by esophagectomy. LNM patterns were analyzed according to the Japanese Classification of Esophageal Cancer (12th Edition), using metrics including lymph node ratio (LNR), lymph node metastasis rate and actual lymph node metastasis rate for specific stations. Postoperative recurrence patterns, overall survival (OS), and event-free survival (EFS) were also evaluated. Results: Compared with nCT, nICT achieved a significantly higher pathological complete response (pCR) rate (22.1% vs. 6.7%, p < 0.001) and a lower metastatic lymph node ratio (LNR) (3.5% vs 6.2%, p < 0.001). Although the overall LNM rate was similar between groups, nICT demonstrated reduced lymph node involvement in several key station lymph nodes, particularly level 7 (along the left gastric artery), with lower the lymph node metastasis rate (LNMR2) (7.6% vs. 14.5%, p = 0.020) and the actual metastasis rate (LNMR3) (8.4% vs. 16.8%, p = 0.012). The overall recurrence/metastasis rate was significantly lower in the nICT group (36.2% vs. 56.8%, p < 0.001), with a notable reduction of recurrence at the anastomotic site. In multivariable analyses, nICT independently predicted lower recurrence risk (adjusted OR = 0.55, p = 0.013) and improved EFS (HR = 0.65, p = 0.001) while OS was not statistically different between groups. Conclusion: In comparison to nCT alone, nICT was significantly associated with deeper pathological response, lower LNM burden, and reduced postoperative recurrence in TESCC.

Keywords: Lymph node metastasis3, neoadjuvant immunochemotherapy2, Prognosis5, recurrence pattern4, thoracic esophageal squamous cell carcinoma1

Received: 08 Dec 2025; Accepted: 16 Feb 2026.

Copyright: © 2026 Liu, Deng, Zheng, Su, Zheng, Lin, Xiao, Shi, Zhang, Fang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xiaohui Chen

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.